Literature DB >> 17634301

Accuracy of six antimicrobial susceptibility methods for testing linezolid against staphylococci and enterococci.

Fred C Tenover1, Portia P Williams, Sheila Stocker, Angela Thompson, Leigh Ann Clark, Brandi Limbago, Roberta B Carey, Susan M Poppe, Dean Shinabarger, John E McGowan.   

Abstract

A challenge panel of enterococci (n = 50) and staphylococci (n = 50), including 17 and 15 isolates that were nonsusceptible to linezolid, respectively, were tested with the Clinical and Laboratory Standards Institute broth microdilution and disk diffusion reference methods. In addition, all 100 isolates were tested in parallel by Etest (AB Biodisk, Solna, Sweden), MicroScan WalkAway (Dade, West Sacramento, CA), BD Phoenix (BD Diagnostic Systems, Sparks, MD), VITEK (bioMérieux, Durham, NC), and VITEK 2 (bioMérieux) by using the manufacturers' protocols. Compared to the results of the broth microdilution method for detecting linezolid-nonsusceptible staphylococci and enterococci, MicroScan results showed the highest category agreement (96.0%). The overall categorical agreement levels for VITEK 2, Etest, Phoenix, disk diffusion, and VITEK were 93.0%, 90.0%, 89.6%, 88.0%, and 85.9%, respectively. The essential agreement levels (results within +/-1 doubling dilution of the MIC determined by the reference method) for MicroScan, Phoenix, VITEK 2, Etest, and VITEK were 99.0%, 95.8%, 92.0%, 92.0%, and 85.9%, respectively. The very major error rates for staphylococci were the highest for VITEK (35.7%), Etest (40.0%), and disk diffusion (53.3%), although the total number of resistant isolates tested was small. The very major error rate for enterococci with VITEK was 20.0%. Three systems (MicroScan, VITEK, and VITEK 2) provided no interpretations of nonsusceptible results for staphylococci. These data, from a challenge panel of isolates, illustrate that the recent emergence of linezolid-nonsusceptible staphylococci and enterococci is providing a challenge for many susceptibility testing systems.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17634301      PMCID: PMC2045282          DOI: 10.1128/JCM.00913-07

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  23 in total

1.  Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals.

Authors:  S K Fridkin; C D Steward; J R Edwards; E R Pryor; J E McGowan; L K Archibald; R P Gaynes; F C Tenover
Journal:  Clin Infect Dis       Date:  1999-08       Impact factor: 9.079

Review 2.  Antimicrobial resistance to linezolid.

Authors:  Venkata G Meka; Howard S Gold
Journal:  Clin Infect Dis       Date:  2004-09-10       Impact factor: 9.079

3.  Linezolid-resistant enterococci: report of the first isolates in the United Kingdom.

Authors:  Cressida Auckland; Louise Teare; Fiona Cooke; Mary E Kaufmann; Marina Warner; Graeme Jones; Kathy Bamford; Helen Ayles; Alan P Johnson
Journal:  J Antimicrob Chemother       Date:  2002-11       Impact factor: 5.790

4.  Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit.

Authors:  A P Johnson; L Tysall; M V Stockdale; N Woodford; M E Kaufmann; M Warner; D M Livermore; F Asboth; F J Allerberger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2002-09-13       Impact factor: 3.267

5.  In vitro activity of linezolid and eperezolid, two novel oxazolidinone antimicrobial agents, against anaerobic bacteria.

Authors:  B H Yagi; G E Zurenko
Journal:  Anaerobe       Date:  1997-10       Impact factor: 3.331

6.  In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species.

Authors:  J H Jorgensen; M L McElmeel; C W Trippy
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

7.  Comparison of agar dilution, disk diffusion, MicroScan, and Vitek antimicrobial susceptibility testing methods to broth microdilution for detection of fluoroquinolone-resistant isolates of the family Enterobacteriaceae.

Authors:  C D Steward; S A Stocker; J M Swenson; C M O'Hara; J R Edwards; R P Gaynes; J E McGowan; F C Tenover
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

Review 8.  Linezolid in vitro: mechanism and antibacterial spectrum.

Authors:  David M Livermore
Journal:  J Antimicrob Chemother       Date:  2003-05       Impact factor: 5.790

9.  Comparison of testing methods for detection of decreased linezolid susceptibility due to G2576T mutation of the 23S rRNA gene in Enterococcus faecium and Enterococcus faecalis.

Authors:  Chao Qi; Xiaotian Zheng; Arlene Obias; Marc H Scheetz; Michael Malczynski; John R Warren
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

10.  Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing.

Authors:  Fred C Tenover; Rajinder K Kalsi; Portia P Williams; Roberta B Carey; Sheila Stocker; David Lonsway; J Kamile Rasheed; James W Biddle; John E McGowan; Bruce Hanna
Journal:  Emerg Infect Dis       Date:  2006-08       Impact factor: 6.883

View more
  18 in total

1.  Increasing incidence of linezolid-intermediate or -resistant, vancomycin-resistant Enterococcus faecium strains parallels increasing linezolid consumption.

Authors:  Marc H Scheetz; Stephanie A Knechtel; Michael Malczynski; Michael J Postelnick; Chao Qi
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

Review 2.  Expert systems in clinical microbiology.

Authors:  Trevor Winstanley; Patrice Courvalin
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

Review 3.  Are we ready for novel detection methods to treat respiratory pathogens in hospital-acquired pneumonia?

Authors:  Andrea Endimiani; Kristine M Hujer; Andrea M Hujer; Sebastian Kurz; Michael R Jacobs; David S Perlin; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2011-05       Impact factor: 9.079

4.  In vitro activity against Staphylococcus aureus of a novel antimicrobial agent, PRF-119, a recombinant chimeric bacteriophage endolysin.

Authors:  Evgeny A Idelevich; Christof von Eiff; Alexander W Friedrich; Domenico Iannelli; Guoqing Xia; Georg Peters; Andreas Peschel; Ingrid Wanninger; Karsten Becker
Journal:  Antimicrob Agents Chemother       Date:  2011-07-11       Impact factor: 5.191

5.  Characterization of nasal and blood culture isolates of methicillin-resistant Staphylococcus aureus from patients in United States Hospitals.

Authors:  Fred C Tenover; Isabella A Tickler; Richard V Goering; Barry N Kreiswirth; José R Mediavilla; David H Persing
Journal:  Antimicrob Agents Chemother       Date:  2011-12-12       Impact factor: 5.191

6.  Comparison of commercial antimicrobial susceptibility test methods for testing of Staphylococcus aureus and Enterococci against vancomycin, daptomycin, and linezolid.

Authors:  Stefan Riedel; Kar Mun Neoh; Stephen W Eisinger; Lisa M Dam; Tsigereda Tekle; Karen C Carroll
Journal:  J Clin Microbiol       Date:  2014-04-09       Impact factor: 5.948

7.  Colistin Resistance in Carbapenem-Resistant Klebsiella pneumoniae: Laboratory Detection and Impact on Mortality.

Authors:  Laura J Rojas; Madiha Salim; Eric Cober; Sandra S Richter; Federico Perez; Robert A Salata; Robert C Kalayjian; Richard R Watkins; Steve Marshall; Susan D Rudin; T Nicholas Domitrovic; Andrea M Hujer; Kristine M Hujer; Yohei Doi; Keith S Kaye; Scott Evans; Vance G Fowler; Robert A Bonomo; David van Duin
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079

8.  Vancomycin MICs for Staphylococcus aureus vary by detection method and have subtly increased in a pediatric population since 2005.

Authors:  Edward O Mason; Linda B Lamberth; Wendy A Hammerman; Kristina G Hulten; James Versalovic; Sheldon L Kaplan
Journal:  J Clin Microbiol       Date:  2009-04-29       Impact factor: 5.948

9.  Investigation of Linezolid Resistance in Staphylococci and Enterococci.

Authors:  Christopher D Doern; Jason Y Park; Michael Gallegos; Debbie Alspaugh; Carey-Ann D Burnham
Journal:  J Clin Microbiol       Date:  2016-03-02       Impact factor: 5.948

10.  Performance of Vitek 2 for antimicrobial susceptibility testing of Staphylococcus spp. and Enterococcus spp.

Authors:  April M Bobenchik; Janet A Hindler; Carmen L Giltner; Sandra Saeki; Romney M Humphries
Journal:  J Clin Microbiol       Date:  2013-11-13       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.